Crimson Publishers Publish With Us Reprints e-Books Video articles

Abstract

Significances of Bioengineering & Biosciences

AGR2 and AKR1B10: Potential Collaborative Markers for Nasopharyngeal Carcinoma Diagnosis and Therapy

  • Open or CloseYuan Tan1, Renhua Fan2, Liguang Lin2, Fang Liu2, Meihua Zhou3 and Lei Wang2*

    1Hunan Key Laboratory of Oncotarget gene and Clinical Laboratory, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University & Hunan Cancer Hospital, China

    2Department of Clinical Laboratory, Changsha Central Hospital, China

    3Changsha KingMed Center for Clinical Laboratory, China.

    *Corresponding author: Lei Wang, Department of Clinical Laboratory, Changsha Central Hospital, Changsha 410004, China

Submission: March 8, 2021;Published: March 26, 2021

DOI: 10.31031/SBB.2021.04.000595

ISSN 2637-8078
Volume 4 Issue 4

Abstract

Nasopharyngeal Carcinoma (NPC) is a common malignant cancer in South China. Previous studies have showed that Anterior Gradient Protein 2 (AGR2) and Aldo-Keto Reductase 1B10 (AKR1B10) progressively increase in NPC primary and metastatic tissues, and AGR2 and AKR1B10 may have the potential to reflect the development of NPC. In this study, we showed that AGR2 and AKR1B10 expressions in NPC tissues were associated with the prognosis of NPC patients, the patients with highly expressed AGR2 and AKR1B10 had a poor prognosis. Consistently, the serum levels of AGR2 and AKR1B10 were markedly higher in NPC patients compared with healthy control, and these concentrations decreased after treatment. Additionally, there was a positive linear correlation between AGR2 and AKR1B10 levels in NPC patients. Furthermore, AGR2 and AKR1B10 showed a positive relationship with Tumor Node Metastasis (TNM) grade and metastasis. Overall, there may be a tight relationship between AGR2 and AKR1B10 expression, and both of them can be used as serum biomarkers to achieve early diagnosis and provide effective therapeutic targets for NPC patients.

Keywords: AGR2; AKR1B10; Serum biomarker; Therapeutic target; Nasopharyngeal carcinoma

Abbreviations: NPC: Nasopharyngeal Carcinoma; AGR2: Anterior Gradient Protein 2; AKR1B10: Aldo- Keto Reductase 1B10; EBV: Epstein-Barr Virus; MMP: Matrix Metalloproteinase; UPR: Unfolded Protein Response; ER: Endoplasmic Reticulum; OS: Overall Survival; ECM: Extracellular Matrix; EGFR: Epidermal Growth Factor Receptor; IGF-1: Insulin-Like Growth Factor-1; DAG: Diacylglycerol; PKC: Protein Kinase C; CTL: Cytotoxic T Lymphocyte; PDI: Protein-Disulfide Isomerase

Get access to the full text of this article

About Crimson

We at Crimson Publishing are a group of people with a combined passion for science and research, who wants to bring to the world a unified platform where all scientific know-how is available read more...

Leave a comment

Contact Info

  • Crimson Publishers, LLC
  • 555 Madison Avenue, 5th floor
  •     New York, NY 10022, USA
  • +1 (929) 600-8049
  • +1 (929) 447-1137
  • info@crimsonpublishers.com
  • www.crimsonpublishers.com